Anti-inflammatory treatments for chronic diseases: A review

Inflammation and Allergy - Drug Targets

Volumn 12, Issue 5, 2013, Pages 349-361

  Laveti, Durgaprasad ^a   Kumar, Manoj ^b   Hemalatha, R ^b   Sistla, Ramakrishna ^c   Naidu, V G M ^a   Talla, Venu ^a   Verma, Vinod ^d   Kaur, Navrinder ^e   Nagpal, Ravinder ^f  

^a NATIONAL INSTITUTE OF PHARMACEUTICAL EDUCATION AND RESEARCH NIPER   (India)

^b NATIONAL INSTITUTE OF NUTRITION   (India)

^c INDIAN INSTITUTE OF CHEMICAL TECHNOLOGY   (India)

^d DEPARTMENT OF CARDIOLOGY   (Singapore)

^e INSTITUTE OF MOLECULAR AND CELL BIOLOGY   (Singapore)

^f JUNTENDO UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

Asthma; Cancer; Cardiovascular disease; CNS disorders; Diabetes; Inflammation; Inflammatory markers; Obesity

Indexed keywords

ACETYLSALICYLIC ACID; ALLICIN; ANTIINFLAMMATORY AGENT; C REACTIVE PROTEIN; CAPTOPRIL; CHEMOKINE RECEPTOR; CYCLOOXYGENASE 1; CYCLOOXYGENASE 2; CYCLOOXYGENASE 3; DEXAMETHASONE; ELLAGIC ACID; ETANERCEPT; GENISTEIN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INFLIXIMAB; INTERLEUKIN 1; INTERLEUKIN 6; INTERLEUKIN 8; LIPOXYGENASE; PARACETAMOL; PIOGLITAZONE; QUERCETIN; RESVERATROL; STAT PROTEIN; TELMISARTAN; THALIDOMIDE; THEOPHYLLINE; TRANSCRIPTION FACTOR AP 1; TUMOR NECROSIS FACTOR ALPHA; UNINDEXED DRUG;

ALZHEIMER DISEASE; ASTHMA; ATHEROSCLEROSIS; CARDIOVASCULAR DISEASE; CENTRAL NERVOUS SYSTEM DISEASE; CHRONIC DISEASE; CHRONIC INFLAMMATION; CHRONIC OBSTRUCTIVE LUNG DISEASE; COLON CANCER; DEPRESSION; DIABETES MELLITUS; DOWN REGULATION; ENTERITIS; GENE EXPRESSION; HUMAN; HYPERTENSION; IMMUNE RESPONSE; METABOLISM; NEOPLASM; NONHUMAN; OBESITY; OSTEOPOROSIS; PARKINSON DISEASE; PROTEIN EXPRESSION; RETINITIS; REVIEW; RHEUMATOID ARTHRITIS; UPREGULATION;

ANIMALS; ANTI-INFLAMMATORY AGENTS; CHRONIC DISEASE; CYTOKINES; HUMANS; IMMUNOTHERAPY; INFLAMMATION; MOLECULAR TARGETED THERAPY; NF-KAPPA B; PROSTAGLANDIN-ENDOPEROXIDE SYNTHASES;

EID: 84888111787     PISSN: 18715281     EISSN: None     Source Type: Journal    
DOI: 10.2174/18715281113129990053     Document Type: Review

References (167)

1. th ed. Academic Press, 2003, pp. 837-860S.
2. Ruan, H.; Miles, P.D.; Ladd, C.M. Profiling gene transcription in vivo reveals adipose tissue as an immediate target of tumor necrosis factoralpha: implications for insulin resistance. Diabetes, 2002, 51, 3176-3188.
3. Langa, A.; Lahava, M.; Sakhninia, E.; Barshackb, I.; Fiddera, H.H.; Avidana, B.; Bardana, E.; Hershkovizc, R.; Meira, S.B.; Chowersa, Y. Allicin inhibits spontaneous and TNF-a induced secretion of proinflammatory cytokines and chemokines from intestinal epithelial cells. Clin. Nutr., 2004, 23, 1199-1208.
4. Mount, M.P.; Lira, A.; Grimes, D.; Smith, P.D.; Faucher, S.; Slack, R.; Anisman, H.; Hayley, S.; Park, D.S. Involvement of interferon-gamma in microglial-mediated loss of dopaminergic neurons. J. Neurosci., 2007, 27, 3328-3337.
5. Howren, M.B.; Lamkin, D.M.; Suls, J. Associations of depression with C-reactive protein, IL-1, and IL-6: a meta-analysis. Psychosom. Med., 2009, 71, 171-186
6. Dowlati, Y.; Herrmann, N.; Swardfager. W.; Liu, H.; Sham, L.; Reim, E.K.; Lanctot K.L. A meta-analysis of cytokines in major depression. Biol. Psychiatry., 2010, 67, 446-457.
7. Kershaw, E.E.; Flier, J.S. Adipose tissue as an endocrine organ. J. Clin. Endocrinal. Metab., 2004, 89, 2548-2556.
8. Miossec, P.; Korn, T.; Kuchroo, V.K. Interleukin-17 and type 17 helper T cells. N. Engl. J. Med., 2009, 361, 888-898.
9. Huising, M. O; Stet, R.J.; Savelkoul, H.F.; Verburg-van Kemenade, B.M.L. The molecular evolution of the interleukin-1 family of cytokines; IL-18 in teleost fish. Dev. Comp. Immunol., 2004, 28, 395-413.
10. Li, Q.; Verma, I.M. NF-kappaB regulation in the immune system. Nat. Rev. Immunol., 2002, 2, 725-734.
11. Hayden, M.S.; Ghosh, S. Signaling to NF-kappaB. Genes Dev., 2004, 18, 2195-2224.
12. Baeuerle, P.A.; Baltimore, D. NF-k B: ten years after. Cell, 1996, 87, 13-20.
13. Baeuerle, P.A.; and Henkle, T. Function and activation of NF-kB in the immune system. Annu. Rev. Immunol., 1994, 12, 141-179.
14. Mercurio, F.; Zhu, H.; Murray, B.W.; Shevchenko, A.; Bennett, B.L.; Li, J.; Young, D.B.; Barbosa, M.; Mann, M.; Manning, A.; Rao, A. IKK-1 and IKK-2: cytokine-activated IkappaB kinases essential for NFkappaB activation. Science, 1997, 278, 860-866.
15. Karin, M. How NF-kappaB is activated: the role of the IkappaB kinase (IKK) complex. Oncogene, 1999, 18, 6867-6874.
16. Chen, Z.J. Ubiquitin signaling in the NF-κB pathway. Nat. Cell Biol., 2005, 7, 758-765.
17. Tak, P.P.; Firestein, G.S. NF-kappaB: a key role in inflammatory diseases. J. Clin. Invest., 2001, 107(1), 7-11.
18. Chen, Z.; Hagler, J.; Palombella, V.J.; Melandri, F.; Scherer, D.; Ballard, D.; Maniatis, T. Signalinduced site-specific phosphorylation targets I kappa B alpha to the ubiquitinproteasome pathway. Genes Dev., 1995, 9, 1586-1597.
19. Sethi, G.; Sung, B.; Aggarwal, B.B. Nuclear factor-{kappa}B activation: from bench to bedside. Exp. Biol. Med., 2008, 233, 21-31.
20. Kaiser, P.; Rothwell, L.; Avery, S.; Balu, S. Evolution of the interleukins. Dev. Comp. Immunol., 2004, 28, 375-394.
21. th ed. 2009, Philadelphia, PA: Elsevier.
22. Ridker, P. M; Hennekens, C.H.; Buring, J.E. C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women. N. Engl. J. Med., 2000, 342, 836-843.
23. Blake, G.J.; Ridker, P.M. Novel clinical markers of vascular wall inflammation. Circ. Res., 2001, 89, 763-771.
24. Festa, A.; Agostino, R.D.; Howard, G. Chronic subclinical inflammation as part of the insulin resistance syndrome. The Insulin Resistance Atherosclerosis Study (IRAS). Circulation, 2000, 102, 42-47.
25. Tchernof, A.; Nolan, A.; Sites, C.K. Weight loss reduces C-reactive protein levels in obese postmenopausal women. Circulation, 2002, 105, 564-569.
26. Hattori, Y.; Matsumura, M.; Kasai K. Vascular smooth muscle cell activation by C-reactive protein. Cardiovasc. Res., 2003, 58, 186-195.
27. Cirillo, P.; Golino, P.; Calabro, P. C-Reactive protein induces tissue factor expression and promotes smooth muscle and endothelial cell proliferation. Cardiovasc. Res., 2005, 68, 47-45.
28. Rocca, B.; Fitz Gerald, G.A. Cyclooxygenases and prostaglandins: shaping up the immune response. Int. Immunopharmacol., 2002, 2, 603-630.
29. Tilley, S.L.; Coffman, T.M.; Koller. B.H. Mixed messages: modulation of inflammation and immune responses by prostaglandins and thromboxanes. J. Clin. Invest., 2001,108,15-23.
30. Mantovani, A.; Allavena, P.; Sica, A.; Balkwill, F. Cancer-related inflammation. Nature, 2008, 454, 436-444.
31. Gaiotti, D.; Chung, J.; Iglesias, M.; Nees, M.; Baker, P.D.; Evans, C.H.; Woodworth, C.D. Tumor necrosis factor-alpha promotes human papillomavirus (HPV) E6/E7 RNA expression and cyclin-dependent kinase activity in HPV-immortalized keratinocytes by a ras-dependent path-way. Mol. Carcinog., 2000, 27, 97-109.
32. Pollard, J.W. Tumor-educated macrophages promote tumor progression and metastasis. Nat. Rev. Cancer, 2004, 4, 71-78.
33. Apte, R.N.; Voronov, E. Interleukin-1, a major pleotropic cytokine in tumor-host interactions. Cancer Biol., 2002, 12, 277-290.
34. Ancrile, B.; Lim, K.H.; Counter, C.M. Oncogenic Ras-induced secretion of IL6 is required for tumorigenesis. Ann. Rev. Immunol., 2007, 14, 649-683.
35. Bollrath, J.; Phesse, T.J.; Burstin, V.A.; Putoczki, T.; Bennecke, M.; Bateman, T.; Nebelsiek, T.; Lundgren-May, T.; Canli, O.; Schwitalla, S.; Matthews, V.; Schmid, R.M.; Kirchner, T.; Arkan, M.C.; Ernst, M.; Greten, F.R. Gp130-mediated Stat3 activation in enterocytes regulates cell survival and cell-cycle progression during colitis-associated tumorigenesis. Cancer Cell, 2009, 15, 91-102.
36. Grivennikov, S.; Karin, E.; Terzic, J.; Mucida, D.; Yu, G.Y.; Vallabhapurapu, S.; Scheller, J.; Rose-John, S.; Cheroutre, H.; Eckmann, L.; Karin, M.; IL-6 and Stat3 are required for survival of intestinal epithelial cells and development of colitis-associated cancer. Cancer Cell, 2009,15, 103-113.
37. Karin, M. The IκB kinase-a bridge between inflammation and cancer. Cell Res., 2008, 18 (3), 334-342.
38. Courtois, G.; Gilmore, T.D. Mutations in the NF-kappaB signaling pathway: implications for human disease. Oncogene, 2006, 25, 6831-6843.
39. Kroop, I.G.; Shackman, N.H. Level of C-reactive protein as a measure of acute myocardial infarction. Proc. Soc. Exp. Biol. Med., 1954, 86, 95-97.
40. Anzai, T.; Yoshikawa, T.; Shiraki, H.; Asakura, Y.; Akaishi, M.; Mitamura, H.; Ogawa, S. C-reactive protein as a predictor of infarct expansion and cardiac rupture after a first Q-wave acute myocardial infarction. Circulation, 1997, 96,778-784.
41. Vasan, R.S.; Sullivan, L.M.; Roubenoff, R.; Dinarello, C.A.; Harris, T.; Benjamin, E.J.; Sawyer, D.B.; Levy, D.; Wilson, P.W.; D'Agostino, R.B. Framingham Heart Study. Inflammatory markers and risk of heart failure in elderly subjects without prior myocardial infarction: the Framingham Heart Study. Circulation, 2003, 107, 1486-1491.
42. Willerson, J.T.; Ridker, P.M. Inflammation as a cardiovascular risk factor. Circulation, 2004, 109, II2-II10.
43. VanEijk, I.C.; Peters, M.J.L.; Serne, E.H. Micro vascular function is impaired in enclosing spondylitis and improves after tumor necrosis factor α blockade. Ann Rheum. Dis., 2009, 68(no.3), 362-366
44. Sattar, N.; Muray, H.M.; Welsh, P.; Blauw, G.J.; Buckley, B.M. Cobbe, S.; de Craen, A. J. M.; Lowe, G.D.; Jukema, J.W.; Macfarlane, P.W.; Murphy, M.B.; Stott, D.J.; Westendorp, R. G. J.; Shepherd, J.; Ford, I.; Packard, C. J. For the prospective study of pravastatin in the elderly at risk (prosper) study group. PLoS Med., 2009, 6. Retrieved from http://dx/doi/org/10.1371/journal.pmed.1000099.
45. Pickup, J.C.; Chusney, G.D.; Thomas, S.M.; Burt, D. Plasma interleukin-6, tumor necrosis factor alpha and blood cytokine production in type 2 diabetes. Life Sci., 2000, 67, 291-300.
46. Bastard, J.P.; Maachi, M.; Lagathu, C.; Kim, M.J.; Caron, M.; Vida, H.; Capeau, J.; Feve, B. Recent advances in the relationship between obesity, inflammation, and insulin resistance. Eur. Cytokine Netw., 2006, 17(1), 4-12.
47. Kershaw, E.E.; Flier, J.S. Adipose tissue as an endocrine organ. J. Clin. Endocrinal Metab., 2004, 89, 2548-2556.
48. Folsom, A.R.; Rosamond, W.D.; Shahar, E. Prospective study of markers of hemostatic function with risk of ischemic stroke. The atherosclerosis risk in communities (ARIC) study investigators. Circulation, 1999, 100(7), 736-742.
49. Grau, A.J.; Buggle, F.; Becher, H.; Werle, E.; Hacke, W. The association of leukocyte count, fibrinogen and C-reactive protein with vascular risk factors and ischemic vascular diseases. Thromb. Res., 1996, 82 (3), 245-255.
50. Shurtz-Swirski, R.; Sela, S.; Herskovits, A.T. Involvement of peripheral polymorphonuclear leukocytes in oxidative stress and inflammation in type 2 diabetic patients. Diabetes Care, 2001, 24(1), 104-110.
51. Hotamisligil, G.S. Inflammation and metabolic disorders. Nature, 2006, 444, 860-867.
52. Hotamisligil G. S.; Shargill N. S.; Spiegelman B. M. Adipose expression of tumor necrosis factor-α: direct role in obesity-linked insulin resistance. Science, 1993, 259(5091), 87-91
53. Karastergiou, K.; Mohamed-Ali, V. The autocrine and paracrine roles of adipokines Mol. Cell. Endocrinol., 2010, 318(1-2), 69-78.
54. Hotamisligil, G.S.; Peraldi, P.; Budavari, A.; Ellis, R.; White, M.F.; Spiegelman, B.M. IRS-1-mediated inhibition of insulin receptor tyrosine kinase activity in TNF-α-and obesity-induced insulin resistance. Science, 1996, 271(5249), 665-668.
55. Wang, B.; Trayhurn, P. Acute and prolonged effects of TNF-α on the expression and secretion of inflammation-related adipokines by human adipocytes differentiated in culture. Pflugers Archiv., 2006, 452 (4), 418-427.
56. Stenlof. K. I; Wernstedt, I.; Allman, T.F.; Wallenius, V.; Wal-lenius, K.; Jansson, J.O. Interleukin-6 levels in the central nervous system are negatively correlated with fat mass in overweight/obese subjects. J. Clin. Endocrinol. Metab., 2003, 88(9), 4379-4383
57. Pradhan, A.D.; Manson, J.E.; Rifai, N.; Buring, J.E.; Ridker, P.M. Creactive protein, interleukin 6, a risk of developing type 2 diabetes mellitus. J. Am. Med. Assoc., 2001, 286(3), 327-323.
58. Gabay, C.; Kushner, I. Acute-phase proteins and other systemic responses to inflammation. N. Engl. J. Med., 1999, 340(6), 448-454.
59. Mundy, G.R. Osteoporosis and inflammation. Nutr. Rev., 2007, 65(12Pt 2), S147-51.
60. Ishihara, K.; Hirano, T. IL-6 in autoimmune disease and chronic inflammatory proliferative disease. Cytokine Growth Factor Rev., 2002, 13, 357-368.
61. Moschen, A.R.; Kaser, A.; Enrich, B.; Ludwiczek, O.; Gabriel, M.; Obrist, P.; Wolf, A.M.; Tilg, H. RANKL/OPG system is activated in inflammatory bowel disease and relates to the state of bone loss. Gut, 2005, 54, 479-487.
62. Koh, J.M.; Kang, Y.H.; Jung, C.H.; Bae, S.; Kim, D.J.; Chung, Y.E.; Kim, G.S. Higher circulating hsCRP levels are associated with lower bone mineral density in healthy pre-and postmenopausal women: evidence for a link between systemic inflammation and osteoporosis. Osteoporosis Int., 2005, 16, 1263-1271.
63. Muller, B. Cytokine imbalance in non immunological chronicdisease. Cytokine, 2002, 18, 334-339.
64. Ganesan, K.; Teklehaimanot, S.; Tran, T.H. Asuncion, M.; Norris, K. Relationship of C-reactive protein and bone mineral density in community-dwelling elderly females. J. Natl. Med. Assoc., 2005, 97, 329-333.
65. Cunnane, G.; Hummel, K.M.; Muller-Ladner, U.; Gay, R.E.; Gay, S. Mechanism of joint destruction in rheumatoid arthritis. Arch. Immunol. Ther. Exp. (Warsz.), 1998, 46,1-7.
66. Vervoordeldonk, M.J.; Tak. P.P. Cytokines in rheumatoid arthritis. Curr. Rheumatol. Rep., 2002, 4, 208-217.
67. Suurmond, J.; Dorjée, A.L.; Boon, M.R.; Knol, E.F.; Huizinga, T.W.J.; Toes R.E.M.; Schuerwegh, A.J.M. Mast cells are the main interleukin 17-positive cells in anticitrullinated protein antibody-positive and-negative rheumatoid arthritis and osteoarthritis synovium. Arthritis Res. Ther., 2011, 13, R150.
68. Kaser, A.; Zeissig, S.; Blumberg, R.S. Inflammatory bowel disease. Annu. Rev. Immunol., 2010, 28, 573-621.
69. Darlington, G.J.; Wilson, D.R.; Lachman, L.B. Monocyte-conditioned medium, interleukin-1, and tumor necrosis factor stimulate the acute phase response in human hepatoma cells in vitro. J. Cell Biol., 1986, 103, 787-793.
70. Desai, D.; Faubion, W.A.; Sandborn, W.J. Biological activity markers in inflammatory bowel disease. Aliment Pharmacol. Ther., 2007, 25, 247-255
71. Mendoza, J.; Abreu, M.T. Biological markers in inflammatory bowel disease: practical consideration for clinicians. Gastroenterol. Clin. Biol., 2009, 33(Suppl 3), S158-173.
72. Lewis, J.D. The utility of biomarkers in the diagnosis and therapy of inflammatory bowel disease. Gastroenterology, 2011,140, 1817-1826. e2
73. Judd, T.A.; Day, A.S.; Lemberg, D.A.; Turner, D.; Leach, S.T. Update of fecal markers of inflammation in inflammatory bowel disease. J. Gastroenterol. Hepatol., 2011, 26, 1493-1499.
74. Saetta, M.; Di Stefano, A.; Maestrelli, P. Activated T-lymphocytes and macrophages in bronchial mucosa of subjects with chronic bronchitis. Am. Rev. Respir. Dis., 1993, 147, 301-306.
75. Noguera, A.; Batle, S.; Miralles, C. Enhanced neutrophil response in chronic obstructive pulmonary disease. Thorax, 2001, 56, 432-437.
76. Profita, M.; Giorgi, R.D.; Sala, A. Muscarinic receptors, leukotriens B4 production and neutrophilic inflammation in COPD patients. Allergy, 2005, 60,1361-1369.
77. Chung, K.F. Inflammatory mediators in chronic obstructive pulmonary disease. Curr. Drug Targets Inflamm. Allergy, 2005, 4, 619-625.
78. Keatings, V.M.; Collins, P.D.; Scott, D.M. Differences in interleukin-8 and tumor necrosis factor-alpha in induced sputum from patients with chronic obstructive pulmonary disease or asthma. Am. J. Respir. Crit. Care Med., 1996, 153, 530-534.
79. deTorres, J.P.; Cordoba-Lanus, E.; Lopez-Aguilar, C. C-reactive protein levels and clinically predictive outcomes in stable COPD patients. Eur. Respir. J., 2006, 27, 902-907.
80. National Institutes of Health, 2002. Global Initiative for Asthma: pocket guide for asthma management and prevention. Bethesda: National Institutes of Health, National Heart, Lung and Blood Institute; Publication no. 02-3659.
81. Kay, A.B. Allergy and allergic diseases. First of two parts. N. Engl. J. Med. 2001, 344, 30-37.
82. Marini, M.; Vittori, E.; Hollemborg, J.; Mattoli, S. Expression of the potent inflammatory cytokines, granulocyte-macrophage-colonystimulating factor and interleukin-6 and interleukin-8, in bronchial epithelial cells of patients with asthma. J. Allergy Clin. Immunol., 1992, 89(5), 1001-1009.
83. Kicic, A.; Sutanto, E.N.; Stevens, P.T.; Knight, D.A.; Stick, S.M. Intrinsic biochemical and functional differences in bronchial epithelial cells of children with asthma. Am. J. Respir. Crit. Care Med., 2006, 174(10), 1110-1118.
84. Dienz, O.; Rincon, M. The effects of IL-6 on CD4 T cell responses. Clin. Immunol. (Orlando, Fla)., 2009, 130(1), 27-33.
85. Acosta-Rodriguez, E.V.; Napolitani, G.; Lanzavecchia, A.; Sallusto, F. Interleukins 1-beta and-6 but not transforming growth factor-beta are essential for the differentiation of interleukin 17 producing human T helper cells. Nat. Immunol., 2007, 8(9), 942-949.
86. Wilson, C.J.; Finch, C.E.; Cohen, H.J. Cytokines and cognition-the case for a head-to-toe inflammatory paradigm. J. Am. Geriatr. Soc., 2002, 50, 2041-2056.
87. Sian-Marie, L., Rothwell N.J. & Gibson, R.M. The role of inflammation in CNS injury and disease. Br. J. Pharmacol., 2006, 147, S232-S240.
88. Raison, C.L.; Capuron, L.; Miller, A.H. Cytokines sing the blues: inflammation and the pathogenesis of depression. Trends Immunol., 2006, 27, 24-31.
89. Raison, C.L.; Lowry, C.A.; Rook, G.A. Inflammation, sanitation, and consternation: loss of contact with co evolved, tolerogenic microorganisms and the pathophysiology and treatment of major depression. Arch. Gen. Psychiatry., 2010, 67, 1211-1224.
90. Capuron, L.; Su, S.; Miller, A.H.; Bremner, J.D.; Goldberg, J.; Vogt, G.J.; Maisano, C.; Jones, L. Murrah, N.V.; Vaccarino, V. Depressive symptoms and metabolic syndrome: is inflammation the underlying link? Biol. Psychiatry, 2008, 64, 896-900.
91. Dantzer, R.O.; Connor, J.C.; Lawson, M.A.; Kelley, K.W. Inflammation-associated depression: from serotonin to kynurenine. Psychoneuroendocrinol., 2011, 36, 426-436.
92. Pace, T.W.; Mletzko, T.C.; Alagbe, O.; Musselman, D.L.; Nemeroff, C.B.; Miller, A.H.; Heim, C.M. Increased stress-induced inflammatory responses in male patients with major depression and increased early life stress. Am. J. Psychiatry, 2006, 163, 1630-1633.
93. Cole, S.W.; Hawkley, L.C.; Arevalo, J.M.; Sung, C.Y.; Rose, R.M.; Cacioppo, J.T. Social regulation of gene expression in human leukocytes. Genome Biol., 2007, 8, R189.
94. Cole, S.W.; Hawkley, L.C.; Arevalo, J.M.; Cacioppo, J.T. Transcript origin analysis identifies antigen-presenting cells as primary targets of socially regulated gene expression in leukocytes. Proc. Natl. Acad. Sci. U.S.A. 2011, 108, 3080-3085.
95. Braak, H.; Tredici, K.D.; Rub, U.; De Vos, R.A.; Jansen Steur, E.N.; Braak, E. Staging of brain pathology related to sporadic Parkinson's disease. Neurobiol., Aging, 2003, 24, 197-211
96. McGeer, P.L.; Itagaki, S.; Boyes, B.E.; McGeer, E.G. Reactive microglia are positive for HLA-DR in the substantia nigra of Parkinson's and Alzheimer's disease brains. Neurology, 1988, 38, 1285-1291.
97. Dobbs, R.J.; Charlett, A.; Purkiss, A.G.; Dobbs, S.M.; Weller, C.; Peterson, D.W. Association of circulating TNF-alpha and IL-6 with ageing and parkinsonism. Acta Neurol Scand., 1999, 19 (1), 34-41.
98. Stypula, G.; Kunert-Radek, J.; Stepien, H.; Zylinska, K.; Pawlikowski, M. Evaluation of interleukins, ACTH, cortisol and prolactin concentrations in the blood of patients with Parkinson's disease. Neuroimmunomodulation, 1996, 3,131-134.
99. Miguel-Carrasco, J.L.; Zambrano, S.; Blanca, A.J.; Mate, A.; Vazquez, C.M. Captopril reduces cardiac inflammatory markers in spontaneously hypertensive rats by inactivation of NF-kB. J. Inflamm., 2010, 7, 21.
100. Beshir, A. B.; Ren, G.; Magpusao, A.N.;. Barone L.M.; Yeung, K.C.; Fenteany, G. Raf kinase inhibitor protein suppresses nuclear factor-kBdependent cancer cell invasion through negative regulation of matrix metalloproteinase expression. Cancer Lett., 2010, 299, 137-149.
101. Ferger, B.; Leng, A.; Mura, A.; Hengerer, B.; Feldon, J. Genetic ablation of tumornecrosis factor-alpha (TNF-alpha) and pharmacological inhibition ofTNF-synthesis attenuates MPTP toxicity in mouse striatum. J. Neurochem., 2004, 89, 822e833.
102. Wang, Q.; Xiang-rong, Z.; Yan-yan, W.; Wei-ping, X.; Wang, H.; Zhang, M. Monocrotaline-induced pulmonary arterial hypertension is attenuated by TNF-α antagonists via the suppression of TNF-α expression and NF-κB pathway in rats. Vascul. Pharmacol., 2012, 58, 71-78.
103. Tripathy, D.; Grammas, P. Acetaminophen inhibits neuronal inflammation and protects neurons from oxidative stress. J. Neuroinflammation, 2009, 6, 10.
104. Xue, H.; Sun, K.; Xie, W.; Hu, G.; Kong, H.; Wang, Q.; Wang, H. Etanercept attenuates short-term cigarette-smoke-exposure-induced pulmonary arterial remodelling in rats by suppressing the activation of TNF-a/NF-kB signal and the activities of MMP-2 and MMP-9. Pulm. Pharmacol. Ther., 2012, 25, 208-215.
105. Ortea, Q.I.; Roschitzki, B.; Ovalles, J.G.; Longo, J.L.; Torre, I.L.; González, I.; Gómez-Reino, J.J.; Gonzalez, A. Discovery of serum proteomic biomarkers for prediction of response to infliximab (a monoclonal anti-TNF antibody) treatment in rheumatoid arthritis: An exploratory analysis. J. Proteom., 2012, 77, 372-382.
106. Vane, J.R. The mode of action of aspirin and similar compounds. J. Allergy Clin. Immunol., 1976, 58, 691-712.
107. Moncada, S.; Ferreira, S.; H.; Vane J.R. Prostaglandins, aspirin-like drugs and the edema of inflammation. Nature, 1973, 246, 217-219.
108. Botting, R.M. Inhibitors of cyclooxygenases: mechanisms, selectivity and uses. J Physiol Pharmacol., 2006, 57 (Suppl. 5), 113-124.
109. Vane, J.R.; Flower, R.J.; Botting, R.M. History of aspirin and its mechanism of action. Stroke, 1990, 21(12 Suppl 4), 12-23.
110. Smith, W.L.; Garavito, R. M; Witt, D.D. Prostaglandin endoperoxide H synthases (Cyclooxygenase)-1 and-2. J. Biol. Chem., 1996, 271, 33157-33160.
111. Xie, W.; Robertson, D.; Simmons, D. Mitogen-inducible prostaglandin G/H synthase: a new target for non-steroidal anti inflammatory drugs. Drug Dev. Res., 1992, 25, 249-265.
112. Hinz, B.; Brune, K. Cyclooxygenase-2-10 years later. J. Pharmacol. Exp. Ther., 2002, 300, 367-375.
113. Peters-Golden, M.; Henderson, W.R. Mechanisms of Disease, Leukotrienes. N. Engl. J. Med., 2007, 357, 1841-1854.
114. Ford-Hutchinson, A.W.; Bray, M.A.; Doig, M.V.; Shipley, M.E.; Smith. M.J. Leukotriene B, a potent chemokinetic and aggregating substance released from polymorphonuclear leukocytes. Nature, 1980, 286, 264-265.
115. Yokomizo, T.; Izumi, T.; Chang, K.; Takuwa, Y.; Shimizu, T. A Gprotein-coupled receptor for leukotriene B4 that mediates chemotaxis. Nature, 1997, 387, 620-624.
116. Hudson, N.; Balsitis, M.; Everitt, S.; Hawkey, C.J. Enhanced gastric mucosa LTB4 synthesis in patients taking non-steroidal antiinflammatory drugs. Gut, 1993,34, 742-747.
117. Celotti, F.; Durand, T. The metabolic effects of inhibitors of 5-lipoxygenase and of cyclooxygenase 1 and 2 are an advancement in the efficacy and safety of anti-inflammatory therapy. Prostaglandins Other Lipid Mediat., 2003, 71, 147-162.
118. Back, M. Inflammatory signalling through leukotriene receptors in atherosclerosis. Curr. Atheroscler. Rep., 2008, 10, 244-251.
119. Mehrabian, M.; Allayee, H.; Wong, J.; Shi, W.; Wang, X.P.; Shaposhnik, Z. Identification of 5-lipoxygenase as a major gene contributing to atherosclerosis susceptibility in mice. Circ. Res., 2002, 91, 120-126.
120. Sternberg, E.M. Neural regulation of innate immunity: a coordinated non-specific host response to pathogens. Nat. Rev. Immunol., 2006, 6, 318-328.
121. Elenkov, I.J.; Chrousos, G.P. Stress system, organization, physiology and immuno regulation. Neuroimmunomodulation, 2006, 13, 257-267.
122. Duma, D.; Jewell, C.M.; Cidlowski, J.A. Multiple glucocorticoid receptor isoforms and mechanisms of post-translational modification. J. Steroid Biochem. Mol. Biol., 2006, 102, 11-15.
123. Kassel, O.; Herrlich, P. Crosstalk between the glucocorticoid receptor and other transcription factors: molecular aspects. Mol. Cell. Endocrinol., 2007, 275, 13-29.
124. Liberman, A.C., Refojo, D., Druker, J., Toscano, M., Rein, T., Holsboer, F., Arzt, E. The activated glucocorticoid receptor inhibits the transcription factor T-bet by direct protein-protein interaction. FASEB J., 2007, 21, 1177-1188.
125. Yang-Yen, H.F.; Chambard, J.C.; Sun, Y.L.; Smeal, T.; Schmidt, T.J.; Drouin, J.; Karin, M. Transcriptional interference between c-Jun and the glucocorticoid receptor: mutual inhibition of DNA binding due to direct protein-protein interaction. Cell, 1990, 62, 1205-1215.
126. Ray, A.; Prefontaine, K.E.; Physical association and functional antagonism between the p65 subunit of transcription factor NF-kB and the glucocorticoid receptor. Proc. Natl. Acad. Sci. U S A, 1994, 91,752-756.
127. Scheinman, R.I.; Gualberto, A.; Jewell, C.M.; Cidlowski, J.A.; Baldwin Jr. A.S. Characterization of mechanisms involved in transrepression of NF-kappa B by activated glucocorticoid receptors. Mol. Cell Biol., 1995, 15, 943-953.
128. Nadeau, S.; Rivest, S. Glucocorticoids play a fundamental role in protecting the brain during innate immune response. J. Neurosci., 2003, 23, 5536-5544.
129. Castano, A.; Herrera, A.J.; Cano, J.; Machado, A.; 2002. The degenerative effect of a single intranigral injection of LPS on the dopaminergic system is prevented by dexamethasone, and not mimicked by rh-TNF-alpha, IL-1beta and IFN-gamma. J. Neurochem., 2002, 81, 150-157.
130. Kurkowaska-Jasterzabska, I.; Litwin, T.; Joniec, I.; Ciesielska, A.; Przybylkowski, A.; Czlonkowski, A.; Czlonkowska, A. Dexamethasone protects against dopaminergic neurons damage in a mouse model of Parkinson's disease. Int. Immunopharmacol., 2004, 4, 1307-1318.
131. Ciulla, M.M.; Paliotti, R.; Esposito, A.; Cuspidi, C.; Muiesan, M.L.; Rosei, E.A.; Magrini, F.; Zanchetti, A. Effects of antihypertensive treatment on ultrasound measures of myocardial fibrosis in hypertensive patients with left ventricular hypertrophy: results of a randomized trial comparing the angiotensin receptor antagonist, candesartan and the angiotensin converting enzyme inhibitor, enalapril. J. Hypertens, 2009, 27, 626-632.
132. Vapaatalo, H.; Mervaala, E.; Nurminen, M.L. Role of endothelium and nitric oxide in experimental hypertension. Physiol. Res., 2000, 49, 1-10.
133. Gonzalez, W.; Fontaine, V.; Pueyo, M.E.; Laquay, N.; Messika-Zeitoun, D.; Philippe, M.; Arnal, J.F.; Jacob, M.P.; Michel, J.B. Molecular plasticity of vascular wall during N(G)-nitro-L-arginine methyl ester-induced hypertension modulation of pro inflammatory signals. Hypertension, 2000, 36,103-109.
134. Hernandez-Presa, M.A.; Bustos, C.; Ortego, M.; Tunon, J.; Ortega, L.; Egido, J.; ACE inhibitor quinapril reduces the arterial expression of NFkappaB dependent proinflammatory factors but not of collagen I in a rabbit model of atherosclerosis. Am. J. Pathol., 1998, 153, 1825-1837.
135. Jahovic, N.; Ercan, F.; Gedik, N.; Yuksel, M.; Sener, G.; Alican, I. The effect of angiotensin-converting enzyme inhibitors on experimental colitis in rats. Regul. Pept., 2005, 130, 67-74.
136. Agha, A.M.; Mansour, M. Effects of captopril on interleukin-6, leukotriene B(4), and oxidative stress markers in serum and inflammatory exudates of arthritic rats: evidence of anti-Inflammatory activity. Toxicol. Appl. Pharmacol., 2000, 168, 123-130.
137. Chaturvedi, R.K.; Beal, M.F. PPAR: a therapeutic target in Parkinson's disease. J. Neurochem., 2008, 106, 506e518.
138. Chung, J.H.; Seo, A.Y.; Chung, S.W.; Kim, M.K.; Leeuwenburgh, C.; Yu, B.P.; Chung, H.Y. Molecular mechanism of PPAR in the regulation of age-related inflammation. Ageing Res. Rev., 2008, 7, 126e136.
139. Dehmer, T., Heneka, M.T., Sastre, M., Dichgans, J., Schulz, J.B., Protection by pioglitazone in the MPTPmodel of Parkinson's disease correlates with I kappa B alpha induction and block of NF kappa B and iNOS activation. J. Neurochem., 2004, 88, 494-501.
140. Gang, J.K.; Kang, Y.S.; Han, S.Y.; Lee, M.H.; Song, H.K.; Han, K.H.; Kim, H.K.; Han, J.Y.; Cha, D.R. Pioglitazone attenuates diabetic nephropathy through an anti-inflammatory mechanism in type 2 diabetic rats. Nephrol. Dial. Transplant, 2008, 23, 2750-2760.
141. Toyama, K.; Nakamura, T.; Kataoka, K.; Yasuda, O.; Fukuda, M.; Tokutomi, Y.; Dong, Y.F.; Ogawa, H.; Kim-Mitsuyama, S. Telmisartan protects against diabetic vascular complications in a mouse model of obesity and type 2 diabetes, partially through peroxisome proliferator activated receptor-c-dependent activity. Biochem. Biophys. Res. Commun., 2011, 410, 508-513.
142. Havsteen, B. Flavanoids, a class of natural products of high pharmacological potency. Biochem. Pharmacol., 1983, 32(7),1141-1148.
143. Middleton, E.; Kandaswami, C.; Theoharides, T. C. The effects of plant flavonoids on mammalian cells: implications for inflammation, heart disease, and cancer. Pharmacol. Rev., 2000, 52(4), 673-751.
144. Havsteen, B.H. The biochemistry and medical significance of the flavonoids. Pharmacol. Ther., 2002, 96 (2-3), 67-202.
145. Matsuda, M.M., Kauss, T.; Kharrat, A.A. Therapeutic and preventive properties of quercetin in experimental arthritis correlate with decreased macrophage inflammatory mediators. Biochem. Pharmacol., 2006, 72(10), 1304-1310.
146. Hamalainen, M.; Nieminen, R.; Vuorela, P.; Heinonen, M.; Moilanen, E. Anti Inflammatory Effects of Flavonoids: Genistein, Kaempferol, Quercetin, and Daidzein Inhibit STAT-1 and NF-κB Activations, Whereas Flavone, Isorhamnetin, Naringenin, and Pelargonidin Inhibit only NF-κB Activation along with Their Inhibitory Effect on iNOS Expression and NO Production in Activated Macrophages. Mediators Inflamm., 2007, 2007, 45673.
147. Suboj, P.; Babykutty, S.; Gopi, D.R.V.; Nair, R.S.; Srinivas, P.; Gopalan, S. Aloe emodin inhibits colon cancer cell migration/angiogenesis by down regulating MMP-2/9, RhoB and VEGF via reduced DNA binding activity of NF-KB. Eur. J. Pharm. Sci., 2012, 45, 581-591.
148. Rosillo, M.A., Sanchez-Hidalgo, M.; Cardeno, A.; Aparicio-Soto, M.; Sánchez-Fidalgo S, Villegas, I.; Lastra C.A.L. Dietary supplementation of an ellagic acid-enriched pomegranate extract attenuates chronic colonic inflammation in rats. Pharmacol. Res., 2012, 66, 235-242.
149. Nair, M.P.; Mahajan, S.; Reynolds, J.L.; Aalinkeel, R.; Nair, H.; Schwartz, S.A.; Kandaswami, C. The flavonoid Quercetin inhibits proinflammatory cytokine (tumor necrosis factor alpha) gene expression in normal peripheral blood mononuclear cells via modulation of the NF-KB system. Clin. Vaccine Immunol., 2006, 13(3), 319-328.
150. Ibrahim A.S.; El-Shishtawy, M.M.; Peña, A.; Liou G.I. Genistein attenuates retinal inflammation associated with diabetes by targeting of microglial activation. Mol. Vis., 2010, 16, 2033-2042.
151. Iiboshi, H.; Ashitani, Ji.; Katoh, S.; Sano, A.; Matsumoto, N.; Mukae, H.; Nakazato, M. Long-term treatment with theophylline reduces neutrophils, interleukin-8 and tumor necrosis factor-a in the sputum of patients with chronic obstructive pulmonary disease. Pulm. Pharmacol. Ther., 2007, 20, 46-51.
152. Bitto, A.; Minutoli, L.; David, A.; Irrera, N.; Rinaldi, M.; Venuti, F.S.; Squadrito, F.; Altavilla, D. Flavocoxid, a dual inhibitor of COX-2 and 5-LOX of natural origin, attenuates the inflammatory response and protects mice from sepsis. Crit. Care, 2012, 16, R32.
153. Abdelwahab, S.I.; Koko, W.S.; Elhassan, T.M.M.; Syam, M.; Achoui, M.; Abdulla, M.A.; Mustafa, M.R.; Ahmad, S.; Noordin, M.I.; Yong, C.L.; Mohd, R.; Sulaiman, R.; Othman, A.; Amir, H. In vitro and in vivo anti-inflammatory activities of columbin through the inhibition of cycloxygenase-2 and nitric oxide but not the suppression of NF-κB translocation Immunopharmacology and Inflammation. Eur. J. Pharmacol., 2012, 678, 61-70.
154. Chatterjee, M.; Das, S.; Janarthan, M.; Ramachandran, H.K.; Chatterjee, M. Role of 5-lipoxygenase in resveratrol mediated suppression of 7, 12-dimethylbenz (α) anthracene-induced mammary carcinogenesis in rats. Eur. J. Pharmacol., 2011, 668, 99-106.
155. Langa, A.; Lahava, M.; Sakhninia, E.; Barshackb, I.; Fiddera, H.H.; Avidana, B.; Bardana, E.; Hershkovizc, R.; Meira, S.B.; Chowersa, Y. Allicin inhibits spontaneous and TNF-a induced secretion of proinflammatory cytokines and chemokines from intestinal epithelial cells. Clin. Nutr., 2004, 23, 1199-1208.
156. Li, J.; Ye, L.; Wang, X.; Liu, J.; Wang, Y.; Zhou, Y.; Ho, W. (-)-Epigallocatechin gallate inhibits endotoxin induced expression of inflammatory cytokines inhuman cerebral microvascular endothelial cells. J. Neuroinflamm., 2012, 9, 161.
157. Weber, W.M.; Hunsaker, L.A.; Roybal, C.N.; Bobrovnikova-Marjon, E.V.; Abcouwer, S.F.; Royer, R.E.; Deck, L.M.; Vander Jagt D.L. Activation of NF kappaB is inhibited by Curcumin and related enones. Bioorg. Med. Chem., 2006, 14, 2450-2461.
158. Bharti, A.C.; Donato, N.; Singh, S.; and Aggarwal, B.B. Curcumin (diferuloylmethane) down-regulates the constitutive activation of nuclear factor-KB and IKBα kinase in human multiple myeloma cells, leading to suppression of proliferation and induction of apoptosis kinase. Blood, 2003, 101,1053-1062.
159. Tunstall, R.G.; Sharma, R.A.; Perkins, S.; Sale, S.; Singh, R.; Farmer, P.B.; Steward, W.P.; Gescher, A.J. Cyclooxygenase-2 expression and oxidative DNA adducts in murine intestinal adenomas: Modification by dietary curcumin and implications for clinical trials. Eur. J. Cancer, 2006, 42, 415-421.
160. Lee, K.W.; Kim, J.H.; Lee, H.J.; Surh, Y.J. Curcumin inhibits phorbol ester induced up-regulation of cyclooxygenase-2 and matrix metalloproteinase-9 by blocking ERK1/2 phosphorylation and NFkappaB transcriptional activity in MCF10A human breast epithelial cells. Antioxid Redox Signal, 2005, 7, 1612-1620.
161. Hong, J.; Bose, M. Ju, J.; Ryu, H.; Chen, X.; Sang, S.; Lee, M.J.; and Yang, C.S. Modulation of arachidonic acid metabolism by curcumin and related beta-diketone derivatives: effects on cytosolic phosphor lipaseA (2), cyclooxygenases and 5-lipoxygenase. Carcinogenesis, 2004, 25, 1671-1679.
162. Prasad, N.S.; Raghavendra, R.; Lokesh, B.R.; Naidu, K.A. Spice phenolics inhibit Human PMNL5-lipoxygenase. Prostaglandins Leukot. Essent. Fatty Acids, 2004, 70, 521-528.
163. Xu, Y.X. Pindolia, K.R.; Janakiraman, N.; Noth, C.J.; Chapman, R.A.; Gautam, S.C. Curcumin, a compound with anti-inflammatory and antioxidant properties, down-regulates chemokine expression in bone marrow stromal cells. Exp. Hematol., 1997, 25(5), 413-422.
164. Shakibaei, M.; Schulze-Tanzil, G.; John, T.; Mobasheri, A. Curcumin protects human chondrocytes from IL-lbeta-induced inhibition of collagen type II and beta1-integrin expression and activation of caspase-3: An immuno morphological study. Ann Anat., 2005, 187, 487-497
165. Sylvester, J.; Liacini, A.; Li, W.Q.; Zafarullah, M. Interleukin-17 signal transduction pathways implicated in inducing matrix metalloproteinase-3,-13 and aggrecanase-1 genes in articular chondrocytes. Cell Signal, 2004, 16, 469-476.
166. Holt, P.R.; Katz, S.; and Kirchhoff, R. Curcumin therapy in inflammatory bowel disease: A pilot study. Dig Dis Sci., 2005, 50, 2191-2193.
167. Nguyen, K.T.; Shaikh, N.; Shukla, K.P.; Su, S.H.; Eberhart, R.C.; Tang, L. Molecular responses of vascular smooth muscle cells and phagocytes to curcumin-eluting bioresorbable stent materials. Biomaterials, 2004, 25, 5333-5346.